The Chennai based drug major Tablets India Ltd (TIL) is planning a major capacity addition as apart of its strategy to develop futuristic drugs and nutraceuticals. The company is also working on to develop some novel drugs with overseas collaborations and strategic tie-ups.
Revealing the developments to Pharmabiz.com, R.K.Jhaver, President & Chief Executive of TIL, said the company is planning to expand its capacity with a view to meet the new market demands. Apart from its existing ISO 9001:2000 certified plants at Chennai, the company would set up two plants at Irungattukottai near Chennai and at a location yet to be finalised, at an investment of over Rs.10 crore. The plants would conform to USFDA standards.
TIL, which is in the process of launching a unique probiotic drug in the market in association with TOA Pharma, a Japanese probiotic major, is in the process of developing more probiotic drugs for various therapeutic segments. The company hopes to launch few more drugs within the next two years.
TIL is in talks with a leading US based company to undertake research to developing amino acid based therapeutic solutions for cancer patients, and to introduce health drinks in the Indian market with another multinational major. However, Jhaver declined to divulge more details as these developments were at nascent stages.
He said, the company has ongoing research projects at IICT - Hyderabad, Annamalai University and JSS College of Pharmacy -Ooty, as part of TIFAC CORE to develop new drugs.
TIL is the first company in the country to introduce the difficult-to-stabilize amino acid-based formulations, incorporating multivitamins, including Vitamin - C, a unique anti-oxidant formula incorporating Glutathione amino acids and amino acid-based anti-peptic ulcerant granules and many other unique nutraceutical products.
The Company has a licence agreement with the erstwhile Japanese multinational Roussel Morishita Co. Ltd. (which later merged with Hoechst Marion Roussel Ltd.), a subsidiary of the world's leader in amino acids - Ajinomoto Corporation Ltd., Japan, since 1971 to manufacture and market Amino acids formulations in India. The company also manufactures and markets certain products in anesthesiology and gastroenterology through its tie up with F. Hoffmann La Roche, Switzerland. TIL also has a tie-up with the Kotobuki Pharmaceuticals Co. Ltd., Japan for a novel anti-gastric and ulcer agent. The company currently exports its drugs to over 30 countries.